<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180724040575N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2020-09-19</date_registration>
      <primary_sponsor>Shahid Beheshti University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the effect of propofol and ketamine on brain oximetry results</public_title>
      <acronym></acronym>
      <scientific_title>comparative effect of propofol and ketamine sedation on cerebral oxymetry results in pediatric cardiac catheterisation</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2020-09-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>44</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/50809</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: Simple randomization by flip the coin  method. The allocation of two sides of a coin to each of the study groups was determined and then the number of coin samples was thrown and recorded, Blinding description: Patients and parents and the registrant of the research questionnaire (about used used medication) are blind. All parents have approved the consent form but are not aware of the grouping The anesthesiologist will prescribe a sedative based on the pre-determined group, but the person recording the questionnaire in the cath. lab. control room is not aware of the groups.</study_design>
      <phase>3</phase>
      <hc_freetext>Diagnostic cardiac catheterization in children.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: ketamine(As an anesthetic drug commonly used in sedation of children undergoing the procedure) is administered intravenously at doses of 1 mg per kg with control of vital signs and hemodynamics. The drug is repeated throughout the procedure based on the patient's reactions and the decision of the responsible anesthesiologist. Number of injections, total dose and duration of procedure and patient recovery time are recorded.Ketamine drug produced by Rotex Medica with an initial concentration of 50 mg / ml, which is diluted to 2 mg / ml is used. Intervention 2: Intervention group: propofol (As an anesthetic drug commonly used in sedation of children undergoing the procedure) is administered intravenously at doses of 1 mg per kg with control of vital signs and hemodynamics. The drug is repeated throughout the procedure based on the patient's reactions and the decision of the responsible anesthesiologist. Number of injections, total dose and duration of procedure and patient recovery time are recorded.Baxter 1% propofol is used, which is diluted up to 2 mg per milliter.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No extra information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Kamal Fani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Modarres Hosp., Saadat abad Ave.,</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>19969111151</zip>
        <telephone>+98 21 2207 4095</telephone>
        <email>kamalfani@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Kamal Fani</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Modarres Hosp., Saadat abad Ave.,</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>19969111151</zip>
        <telephone>+98 21 2207 4095</telephone>
        <email>kamalfani@sbmu.ac.ir</email>
        <affiliation>Shahid Beheshti University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Children referring to the cath lab. of Shahid Modares Hospital for diagnostic cardiac catheterization</inclusion_criteria>
      <agemin>6 months</agemin>
      <agemax>60 months</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Parental dissatisfaction
Known allergy to ketamine or propofol
History of seizure or other neurological diseases</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: ketamine(As an anesthetic drug commonly used in sedation of children undergoing the procedure) is administered intravenously at doses of 1 mg per kg with control of vital signs and hemodynamics. The drug is repeated throughout the procedure based on the patient's reactions and the decision of the responsible anesthesiologist. Number of injections, total dose and duration of procedure and patient recovery time are recorded.Ketamine drug produced by Rotex Medica with an initial concentration of 50 mg / ml, which is diluted to 2 mg / ml is used.</i_keyword>
      <i_keyword>Intervention group: propofol (As an anesthetic drug commonly used in sedation of children undergoing the procedure) is administered intravenously at doses of 1 mg per kg with control of vital signs and hemodynamics. The drug is repeated throughout the procedure based on the patient's reactions and the decision of the responsible anesthesiologist. Number of injections, total dose and duration of procedure and patient recovery time are recorded.Baxter 1% propofol is used, which is diluted up to 2 mg per milliter.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Cerebral oximetry number by near infrared spectroscopy. Timepoint: Before and after catheterization every 5 minutes to the end of the procedure and transfer to the recovery room. Method of measurement: Near infrared spectroscopy.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Heart beat. Timepoint: 5 minutes. Method of measurement: By pulse oximetry and electrocardiogram monitoring device.</sec_outcome>
      <sec_outcome>Blood oxygen saturation. Timepoint: 5 minutes. Method of measurement: By pulse oximetry device.</sec_outcome>
      <sec_outcome>Blood pressure. Timepoint: 5 minutes. Method of measurement: by non-invasive sphygmomanometer.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shahid Beheshti University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2019-12-15</approval_date>
        <contact_name>Ethics committee of shahid beheshti University of Medical Sciences</contact_name>
        <contact_address>Taleghani Hospital, velenjak, Tehran. Iran Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
